Cantargia ABCHIX:CANTAS 37 Market Cap is kr533.5 Mil as of Jun. 28, 2026. GuruFocus rates CHIX:CANTAS with a GF Score™ of 37/100. The stock has 2 warning signs investors should review. Among 1,429 Biotechnology companies, Cantargia AB ranks worse than 60.81% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Cantargia AB's share price for the quarter that ended in Mar. 2026 was kr4.174. Cantargia AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 248.6 Mil. Therefore, Cantargia AB's market cap for the quarter that ended in Mar. 2026 was kr1,037.7 Mil.
Cantargia AB's quarterly market cap
stayed the same
from Sep. 2025 (kr1,037.7 Mil) to Dec. 2025 (kr1,037.7 Mil) and
stayed the same
from Dec. 2025 (kr1,037.7 Mil) to Mar. 2026 (kr1,037.7 Mil).
Cantargia AB's annual market cap
stayed the same
from Dec. 2023 (kr766.7 Mil) to Dec. 2024 (kr766.7 Mil) but then
increased
from Dec. 2024 (kr766.7 Mil) to Dec. 2025 (kr1,037.7 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Cantargia AB's Enterprise Value for Today is kr474.0 Mil.
Cantargia AB (CHIX:CANTAs) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Cantargia AB Market Cap Related Terms
Cantargia AB Market Cap Historical Data
* Premium members only.
The historical data trend for Cantargia AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:CANTAS vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Cantargia AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cantargia AB Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cantargia AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Cantargia AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Cantargia AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cantargia AB (CHIX:CANTAS) has a Market Cap of kr533.5 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cantargia AB and its competitors. According to the industry distribution chart, Cantargia AB ranks #869 out of 1429 companies in the Biotechnology industry, placing it in the top 60.8%.
Is Cantargia AB's Market Cap too high?
Cantargia AB's current Market Cap is kr533.5 Mil. Based on the distribution chart, Cantargia AB ranks #869 out of 1429 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cantargia AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Cantargia AB's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cantargia AB ranks #869 out of 1429 companies for Market Cap. This places Cantargia AB in the lower half of its industry. The industry median Market Cap is 112.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.70, based on 1,429 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cantargia AB and its competitors. For the Biotechnology industry, the median Market Cap is 112.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cantargia AB's current Market Cap is kr533.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantargia AB stock overvalued right now?
Cantargia AB (CHIX:CANTAS) has a current Market Cap of kr533.5 Mil. The current Market Cap is kr533.5 Mil. Cantargia AB's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Cantargia AB (CHIX:CANTAS), the current Market Cap is kr533.5 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
37GF Score
Get the complete analysis for CHIX:CANTAS
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CANTAS has been successfully added to your 
